Literature DB >> 31714959

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Guillermo F Sanz1,2,3, Mariam Ibañez1,3,4, Esperanza Such1,3,4.   

Abstract

This article has a companion Point by Thol and Platzbecker.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Year:  2019        PMID： 31714959      PMCID： PMC6855105          DOI： 10.1182/bloodadvances.2019000680

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  42 in total

1.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors:  Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

2.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Authors:  R Itzykson; O Kosmider; T Cluzeau; V Mansat-De Mas; F Dreyfus; O Beyne-Rauzy; B Quesnel; N Vey; V Gelsi-Boyer; S Raynaud; C Preudhomme; L Adès; P Fenaux; M Fontenay
Journal:  Leukemia       Date:  2011-04-15       Impact factor: 11.528

3.  Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.

Authors:  Ayalew Tefferi; Terra L Lasho; Mrinal M Patnaik; Lyla Saeed; Mythri Mudireddy; Dame Idossa; Christy Finke; Rhett P Ketterling; Animesh Pardanani; Naseema Gangat
Journal:  Am J Hematol       Date:  2017-10-20       Impact factor: 10.047

4.  Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Authors:  Uwe Platzbecker; Ulrich Germing; Katharina S Götze; Philipp Kiewe; Karin Mayer; Jörg Chromik; Markus Radsak; Thomas Wolff; Xiaosha Zhang; Abderrahmane Laadem; Matthew L Sherman; Kenneth M Attie; Aristoteles Giagounidis
Journal:  Lancet Oncol       Date:  2017-09-01       Impact factor: 41.316

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

6.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

7.  Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).

Authors:  M Mossner; J-C Jann; D Nowak; U Platzbecker; A Giagounidis; K Götze; A Letsch; D Haase; K Shirneshan; F Braulke; R F Schlenk; T Haferlach; P Schafhausen; G Bug; M Lübbert; A Ganser; G Büsche; E Schuler; V Nowak; J Pressler; J Obländer; S Fey; N Müller; E Lauinger-Lörsch; G Metzgeroth; C Weiß; W-K Hofmann; U Germing; F Nolte
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

Review 8.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

9.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

10.  Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

Authors:  M Teresa Cedena; Inmaculada Rapado; Alejandro Santos-Lozano; Rosa Ayala; Esther Onecha; María Abaigar; Esperanza Such; Fernando Ramos; José Cervera; María Díez-Campelo; Guillermo Sanz; Jesús Hernández Rivas; Alejandro Lucía; Joaquin Martínez-López
Journal:  Oncotarget       Date:  2017-10-27
View more
  1 in total

1.  Guideline-based indicators for adult patients with myelodysplastic syndromes.

Authors:  Kristina Stojkov; Tobias Silzle; Georg Stussi; David Schwappach; Juerg Bernhard; David Bowen; Jaroslav Čermák; Avinash G Dinmohamed; Corien Eeltink; Sabrina Eggmann; Pierre Fenaux; Ulrich Germing; Manuel Haschke; Eva Hellstrom-Lindberg; Monika Heger; Arjan A van de Loosdrecht; Jakob Passweg; Michael Pfeilstöcker; Uwe Platzbecker; Luca Malcovati; António Medina de Almeida; Moshe Mittelman; Christine Morgenthaler; David P Steensma; Valeria Santini; Reinhard Stauder; Argiris Symeonidis; Sämi Schär; Charlotte Maddox; Theo de Witte; Julia Bohlius; Nicolas Bonadies
Journal:  Blood Adv       Date:  2020-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.